fda status bpc 157 2026 BPC-157 Legal Status: Regulations and Compounding FDA Schedules July 2026 PCAC

At 1.2 mg, the therapeutic sweet spot begins to emerge

For digestive issues, symptom scores, inflammatory markers, and potentially repeat endoscopy or permeability testing help assess response

The MHRA, in April 2026, has effectively made the same call

Unlike enrolling in a formal clinical trial (which has extensive consent forms explaining experimental status), patients at wellness clinics might assume if a doctor offered it, it must be safe or allowed. Such misunderstandings could lead to feelings of betrayal and litigation if things go wrong

(FDA dockets) Scope creep : The May 12 analysis also named additional peptide-related substances FDA expects to evaluate at a later advisory committee meeting before February 2027, including LL-37, dihexa acetate, injectable GHK-Cu, PEG-MGF, and melanotan II

This favors the possible controlling role of the BPC 157